SNV1521 / Synnovation Therap - LARVOL DELTA

The potent and selective PARP1 inhibitor and trapper SNV1521 exhibits combination activity with targeted and chemotherapeutics (AACR 2025) - "When comparing with the target efficacious concentration using a BRCA2-deficient cell line versus the NOEL for suppression of heme progenitors, SNV1521 showed an expanded margin versus either olaparib or saruparib...In a PDX model of breast cancer, the combination of topotecan with SNV1521 showed deeper tumor regression than either agent alone. Moreover, this activity showed durable anti-tumor activity after cessation of dosing. In summary, these data support the continued clinical development of SNV1521 as monotherapy and also in combination with drugs that are mechanistically synergistic but cannot be effectively combined with less selective PARP1 inhibitors because of overlapping toxicities."

Breast Cancer • Oncology • Solid Tumor • BRCA • BRCA2 • PARP2

SNV1521-101: SNV1521 in Participants with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Synnovation Therapeutics, Inc. | N=76 ➔ 200

Enrollment change • Oncology • Prostate Cancer • Solid Tumor

SNV1521-101: SNV1521 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Synnovation Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors (Businesswire) - "Synnovation Therapeutics...announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors. SNV1521 is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor."

Trial status • Oncology • Solid Tumor

SNV1521 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=76 | Not yet recruiting | Sponsor: Synnovation Therapeutics, Inc.

Metastases • New P1 trial • Oncology • Solid Tumor

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways (Businesswire) - "Synnovation Therapeutics...launched today with a $102 million Series A. The financing was led by Third Rock Ventures with participation from Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management....Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs....The company is initiating a Phase I study and anticipates dosing its first patient in the coming weeks."

Financing • New P1 trial • Oncology